These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27820637)

  • 1. Knowing When and How to Use Medical Products: A Shared Responsibility for the FDA and CMS.
    Califf RM; Sherman RE; Slavitt A
    JAMA; 2016 Dec; 316(23):2485-2486. PubMed ID: 27820637
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential legal barriers to increasing CMS/FDA collaboration: the law of trade secrets and related considerations.
    Wang SS; Smith JJ
    Food Drug Law J; 2003; 58(4):613-27. PubMed ID: 15027453
    [No Abstract]   [Full Text] [Related]  

  • 3. Current and future state of FDA-CMS parallel reviews.
    Messner DA; Tunis SR
    Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From proposal to patient: how CMS makes coverage decisions.
    Turnbull GB
    Ostomy Wound Manage; 2002 Apr; 48(4):8-10, 82. PubMed ID: 11993063
    [No Abstract]   [Full Text] [Related]  

  • 5. Exploring options for improving healthcare.
    Wang SS; Mendelson DN; Schulman KA; Mark DB
    Am Heart J; 2004 Jan; 147(1):23-30. PubMed ID: 14691414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The case for a new national program for the development of cancer therapeutics.
    Schein PS
    J Clin Oncol; 2001 Jun; 19(12):3142-53. PubMed ID: 11408512
    [No Abstract]   [Full Text] [Related]  

  • 7. Translation of cancer immunotherapies.
    Mulé JJ; Weber JS
    Nat Med; 2004 Nov; 10(11):1153; author reply 1153-4. PubMed ID: 15516900
    [No Abstract]   [Full Text] [Related]  

  • 8. Median approval times for class III medical devices have been well above statutory deadlines set for FDA and CMS.
    Zinn AM; Allen JC; Hacker CS
    Health Aff (Millwood); 2012 Oct; 31(10):2304-13. PubMed ID: 23048112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mandatory Shared Decision Making by the Centers for Medicare & Medicaid Services for Cardiovascular Procedures and Other Tests.
    Merchant FM; Dickert NW; Howard DH
    JAMA; 2018 Aug; 320(7):641-642. PubMed ID: 29868828
    [No Abstract]   [Full Text] [Related]  

  • 10. Using the MADIT II criteria for implantable cardioverter defibrillators-what is the role of the Food and Drug Administration approval?
    Barold HS
    Card Electrophysiol Rev; 2003 Dec; 7(4):443-6. PubMed ID: 15071272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NIH, FDA setting up research centers to generate evidence base to inform tobacco regulation.
    Mitka M
    JAMA; 2013 Oct; 310(15):1550. PubMed ID: 24129450
    [No Abstract]   [Full Text] [Related]  

  • 12. Active surveillance of postmarket medical product safety in the Federal Partners' Collaboration.
    Robb MA; Racoosin JA; Worrall C; Chapman S; Coster T; Cunningham FE
    Med Care; 2012 Nov; 50(11):948-53. PubMed ID: 23047784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical and Medical Devices: FDA Oversight.
    White RS;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-97. PubMed ID: 27116797
    [No Abstract]   [Full Text] [Related]  

  • 14. The disconnect between the HCFA and the FDA.
    Firth BG
    J Invasive Cardiol; 2001 Feb; 13(2):136-8; discussion 158-70. PubMed ID: 11176025
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain.
    Chambers JD; May KE; Neumann PJ
    Health Aff (Millwood); 2013 Jun; 32(6):1109-15. PubMed ID: 23733986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.
    Roginiel AC; Dhruva SS; Ross JS
    Medicine (Baltimore); 2018 Oct; 97(40):e12715. PubMed ID: 30290675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A turbulent year at the agency.
    Ratner M
    Nat Biotechnol; 2006 Feb; 24(2):145-51. PubMed ID: 16465153
    [No Abstract]   [Full Text] [Related]  

  • 18. Science and regulation. FDA's approach to regulation of products of nanotechnology.
    Hamburg MA
    Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
    [No Abstract]   [Full Text] [Related]  

  • 19. Rational dispersion for the introduction of transcatheter valve therapy.
    Mack MJ; Holmes DR
    JAMA; 2011 Nov; 306(19):2149-50. PubMed ID: 22089724
    [No Abstract]   [Full Text] [Related]  

  • 20. Former FDA Commissioner heads CMS.
    FDA Consum; 2004; 38(3):6. PubMed ID: 15218834
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.